Compare Biogen Inc (BIIB) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Biogen Inc trades at $195.51 (market cap $28.34B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.15. The key difference: Biogen Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | XDTE | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $216.63 | $44.76 |
52-Week Low | $122.68 | $36.00 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
XDTE is trading at $38.91, down 0.74% on the day, with a bearish technical signal from moving averages. The ETF focuses on generating high income through a 0DTE covered call strategy on the S&P 500, offering frequent dividend distributions. Recent news highlights its role in providing daily and weekly income, though some sources note risks associated with potential NAV erosion.
The outlook for XDTE centers on its high-yield income strategy, but investors face significant risks from market volatility and NAV decline. While the fund appeals for tax-efficient weekly payouts, its performance is highly sensitive to S&P 500 movements and options market conditions, warranting caution amid bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
